Study Summary
Phase I, interventional, single-arm, open-label, treatment study to evaluate the safety and effectiveness of CD33-CLL1 CAR in patients with relapsed and/or refractory acute myeloid leukemia (AML).
Want to learn more about this trial?
Request More InfoInterventions
FludarabineDRUG
recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
CytoxanDRUG
recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.
Dual CD33-CLL1 CAR-T cellsBIOLOGICAL
CD33-CLL1 CAR-T infusion (starting at dose level 1 \[DL1\]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Department of Hematology, Xinqiao Hospital | Chongqing | Chongqing Municipality | China |